Lynk Solutec has completed a U.S. patent application for its proprietary endoscopic coating technology, marking a significant milestone in the company’s efforts to expand into the global medical device market. This application follows the company’s domestic patent for its anti-fogging endoscopic coating agent and specialized certification, further validating the global applicability of Lynk Solutec’s innovative technology.

With this U.S. patent application, the company’s “Lynk Coating” technology has gained greater potential for adoption in the international medical device arena. Lynk Solutec plans to actively pursue global market expansion and technology licensing opportunities based on this advancement. The technology offers a groundbreaking solution that enhances surgical visibility and prevents the adhesion of biological substances, ultimately improving both procedural efficiency for medical professionals and safety for patients.

Looking ahead, Lynk Solutec aims to continue its growth in the global healthcare market through the development of next-generation coating technologies. The company is also committed to securing additional international certifications and strengthening global partnerships to ensure its solutions are widely adopted across diverse medical environments worldwide.

Lynk Solutec, a medical device surface coating technology company led by CEO Jungmok Seo, has announced the acquisition of two innovative coating technology patents that can significantly enhance safety in medical settings. The newly registered patents are for “Medical Implant Coating Composition for Foreign Material Prevention” and “Suture Coating Composition for Foreign Material Prevention.”

The core of these newly developed coating technologies lies in their special composition that fundamentally prevents the adhesion of all foreign materials, including blood, moisture, mucus, and bacteria. CTO Yeonteak Lee explained, “Medical implants and sutures come into contact with various foreign substances within the body, such as blood, mucus, bacteria, cells, and calcification. The adhesion of these substances can cause serious side effects, including infections, inflammation, and thrombosis formation. These patent technologies provide an innovative solution that fundamentally addresses these issues.”

The implant coating technology can be applied to a wide range of medical devices, including various types of stents for the esophagus, blood vessels, bile duct, gallbladder, pancreas, uterus, urethra, and ureter, as well as drainage catheters, injection catheters, parenteral catheters, and urological catheters. The suture coating technology is applicable to all types of sutures, including dental/ophthalmic and microsurgical sutures. Notably, unlike existing coating technologies, these new innovations allow for additional lubricant coating on top of the coated medical devices, further enhancing their performance.

CEO Jungmok Seo emphasized, “These patent technologies can dramatically reduce medical device-related complications. In particular, they can significantly improve the safety and accuracy of surgical procedures by minimizing the risks of infection, inflammation, and thrombosis formation.” He also added, “We are currently preparing for clinical trials to commercialize these patent technologies and plan to complete product development in the near future.”

Lynk Solutec, a spin-off company from the BioLogical Interfaces and Sensor Systems Laboratory at Yonsei University, continues to drive innovation in medical settings through its medical device coating technologies.

Jung-mok Seo, CEO of Lynk Solutec, a company developing innovative medical devices based on medical device coating technology, was invited as a speaker at the 2024 Yonsei University Laboratory Startup Conference.

During the event, CEO Seo presented successful cases of technology startups as a professor in the Department of Electrical and Electronic Engineering. Leading the Yonsei University BioLogical Interface and Sensor Systems Laboratory, he developed a coating technology that can fundamentally inhibit infection, inflammation, and thrombosis for the first time in the world. He shared vibrant examples of how he is expanding his business by showcasing innovative medical devices such as “an endoscopic cap that provides a clear surgical view” and “a ureteral stent that inhibits calcification”

In the following “Laboratory Startup Talk Concert,” he participated in a panel discussion with the Yonsei University Startup Support Team. CEO Seo shared insights on the development direction and challenges of the laboratory startup ecosystem, drawing significant interest from the audience.